The Essen Stroke Risk Score predicts recurrent cardiovascular events A validation within the REduction of Atherothrombosis for Continued Health (REACH) registry

Stroke

Volumn 40, Issue 2, 2009, Pages 350-354

  Weimar, Christian ^a   Diener, Hans Christoph ^a   Alberts, Mark J ^b   Gabriel Steg, P ^c   Bhatt, Deepak L ^d   Wilson, Peter W F ^e   Mas, Jean Louis ^f   Röther, Joachim ^g  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b NORTHWESTERN UNIVERSITY   (United States)

^c BICHAT HOSPITAL   (France)

^d LERNER RESEARCH INSTITUTE   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CENTRE HOSPITALIER SAINTE ANNE   (France)

^g HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Ischemic stroke; Risk prediction; Secondary prevention; Vascular events

Indexed keywords

AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE CONTROL; DISEASE REGISTRY; ESSEN STROKE RISK SCORE; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTPATIENT CARE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; RISK ASSESSMENT; SCORING SYSTEM; STROKE; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; VALIDATION STUDY; AGE; AREA UNDER THE CURVE; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; GERMANY; PREDICTION AND FORECASTING; REGISTER; REPRODUCIBILITY;

AGE FACTORS; AGED; AREA UNDER CURVE; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; COHORT STUDIES; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; PREDICTIVE VALUE OF TESTS; RECURRENCE; REGISTRIES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; STROKE;

EID: 60549096073     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.521419     Document Type: Article

References (17)

1. Hankey GJ. Long-term outcome after ischaemic stroke/transient ischaemic attack. Cerebrovasc Dis. 2003;16(suppl 1):14-19.
2. Touze E, Varenne O, Chatellier G, Peyrard S, Rothwell PM, Mas JL. Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke:a systematic review and meta-analysis. Stroke. 2005;36:2748-2755.
3. Diener HC. Stroke prevention:anti-platelet and anti-thrombolytic therapy. Neurol Clin. 2000;18:343-355.
4. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile:adjustment for antihypertensive medication. The Framingham study. Stroke. 1994;25:40-43.
5. Moons KG, Bots ML, Salonen JT, Elwood PC, Freire de Concalves A, Nikitin Y, Sivenius J, Inzitari D, Benetou V, Tuomilehto J, Koudstaal PJ, Grobbee DE. Prediction of stroke in the general population in Europe (EUROSTROKE):is there a role for fibrinogen and electrocardiography? J Epidemiol Community Health. 2002;56(suppl l):i30-36.
6. Hankey GJ, Slattery JM, Warlow CP. Transient ischaemic attacks:which patients are at high (and low) risk of serious vascular events? J Neurol Neurosurg Psychiatry. 1992;55:640-652.
7. Kernan WN, Viscoli CM, Brass LM, Makuch RW, Sarrel PM, Roberts RS, Gent M, Rothwell P, Sacco RL, Liu RC, Boden-Albala B, Horwitz RI. The Stroke Prognosis Instrument II (SPI II):a clinical prediction instrument for patients with transient ischemia and nondisabling ischemic stroke. Stroke. 2000;31:456-462.
8. CAPRIE Steering Committee. A randomised, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet. 1996;348:1329-1339.
9. Diener HC, Ringleb PA, Savi P. Clopidogrel for the secondary prevention of stroke. Exp Opin Pharmacother. 2005;6:755-764.
10. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13.
11. Diener HC. Modified-release dipyridamole combined with aspirin for secondary stroke prevention. Aging Health. 2005;1:19-26.
12. Weimar C, Goertler M, Rother J, Ringelstein EB, Darius H, Nabavi DG, Kim IH, Benemann J, Diener HC. Predictive value of the Essen stroke risk score and ankle brachial index in acute ischemic stroke patients from 85 German stroke units. J Neurol Neurosurg Psychiatry. 2008;79:1339-1343.
13. Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, Mas JL, Richard AJ, Rother J, Wilson PW;REACH Registry Investigators. The REduction of Atherothrombosis for Continued Health (REACH) Registry:an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006;151:786.el-10.
14. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Rother J, Wilson PW. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180-189.
15. Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, Röther J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S;REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197-1206.
16. Lichtman JH, Krumholz HM, Wang Y, Radford MJ, Brass LM. Risk and predictors of stroke after myocardial infarction among the elderly:results from the Cooperative Cardiovascular Project. Circulation. 2002;105:1082-1087.
17. Hankey GJ, Slattery JM, Warlow CP. Can the long term outcome of individual patients with transient ischaemic attacks be predicted accurately? J Neurol Neurosurg Psychiatry. 1993;56:752-759.